These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 26171179)
1. Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach. Giordano G; Mondello P; Tambaro R; Perrotta N; D'Amico F; D'Aveta A; Berardi G; Carabellese B; Patriarca A; Corbi GM; DI Marzio L; Licianci A; Berardi D; DI Lullo L; DI Marco R Mol Clin Oncol; 2015 Jul; 3(4):781-784. PubMed ID: 26171179 [TBL] [Abstract][Full Text] [Related]
2. Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study. Hustrini NM; Siregar P; Setiawati A; Nugroho P Acta Med Indones; 2019 Jul; 51(3):230-237. PubMed ID: 31699946 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis. Broccoli A; Argnani L; Stefoni V; Gandolfi L; Zinzani PL Hematol Oncol; 2018 Feb; 36(1):136-143. PubMed ID: 28332724 [TBL] [Abstract][Full Text] [Related]
4. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Aapro M; Cornes P; Sun D; Abraham I Ther Adv Med Oncol; 2012 May; 4(3):95-105. PubMed ID: 22590483 [TBL] [Abstract][Full Text] [Related]
5. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology. Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032 [TBL] [Abstract][Full Text] [Related]
6. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia. Thanakitcharu P; Siriwiwatanakul N J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706 [TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963 [TBL] [Abstract][Full Text] [Related]
8. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. Kurtz JE; Soubeyran P; Michallet M; Luporsi E; Albrand H Onco Targets Ther; 2016; 9():6689-6693. PubMed ID: 27822071 [TBL] [Abstract][Full Text] [Related]
9. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409 [TBL] [Abstract][Full Text] [Related]
10. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl. Hörl WH; Locatelli F; Haag-Weber M; Ode M; Roth K; Clin Nephrol; 2012 Jul; 78(1):24-32. PubMed ID: 22732334 [TBL] [Abstract][Full Text] [Related]
11. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U; Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476 [TBL] [Abstract][Full Text] [Related]
12. [Phase II clinical study of recombinant human erythropoietin on the anemia of myelodysplastic syndrome]. Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T Rinsho Ketsueki; 1993 Aug; 34(8):928-36. PubMed ID: 8411647 [TBL] [Abstract][Full Text] [Related]
13. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466 [TBL] [Abstract][Full Text] [Related]
14. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Provenzano R; Bhaduri S; Singh AK; Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787 [TBL] [Abstract][Full Text] [Related]
15. The emerging role of biosimilar epoetins in nephrology in the United States. Fishbane S; Shah HH Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283 [TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Patel M; Thimons DG; Winston JL; Langholff W; McGowan T J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Haag-Weber M; Vetter A; Thyroff-Friesinger U; Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881 [TBL] [Abstract][Full Text] [Related]
18. An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Mustacchi G; Ceccherini R; Dellach C; Foladore S; Milani S; Leita M; Sisto M Ann Oncol; 2006 Nov; 17(11):1705-8. PubMed ID: 16980603 [TBL] [Abstract][Full Text] [Related]
19. [Guidelines for the treatment of anemia in chronic renal failure]. Triolo G; G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504 [TBL] [Abstract][Full Text] [Related]
20. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study. Dellanna F; Fluck RJ; Lonnemann G; Wild CA; Iwanowitsch A; Meissner R; Audhya P Clin Nephrol; 2015 Nov; 84(5):280-8. PubMed ID: 26396097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]